Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2021 16:30 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

ALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program for gout and chronic kidney disease; initial data expected in Q4 2021June KOL webinar highlighted...
August 03, 2021 16:15 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
August 03, 2021 16:05 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...
July 13, 2021 23:43 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
July 12, 2021 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Provides Update on Clinical Development Programs

-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021- -Reloxaliase advancing in URIROX-2 Pivotal Phase 3...
July 08, 2021 16:17 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...
July 07, 2021 16:15 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...
June 08, 2021 16:15 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...
June 08, 2021 08:30 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease

NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class...
May 11, 2021 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 ---- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data...